Campbell & CO Investment Adviser LLC Raises Stake in Hologic, Inc. (NASDAQ:HOLX)

Campbell & CO Investment Adviser LLC grew its stake in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) by 3.5% in the third quarter, HoldingsChannel reports. The fund owned 7,893 shares of the medical equipment provider’s stock after buying an additional 265 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in Hologic were worth $548,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Deseret Mutual Benefit Administrators increased its stake in shares of Hologic by 312.4% during the 2nd quarter. Deseret Mutual Benefit Administrators now owns 367 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 278 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in shares of Hologic during the 3rd quarter valued at about $29,000. NBC Securities Inc. acquired a new position in shares of Hologic during the 3rd quarter valued at about $33,000. Clear Street Markets LLC increased its stake in shares of Hologic by 91.3% during the 1st quarter. Clear Street Markets LLC now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 231 shares during the last quarter. Finally, Salem Investment Counselors Inc. increased its stake in shares of Hologic by 163.9% during the 2nd quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 341 shares during the last quarter. Institutional investors and hedge funds own 92.64% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on HOLX shares. Raymond James upped their price objective on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Morgan Stanley dropped their target price on shares of Hologic from $86.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, November 13th. UBS Group increased their target price on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Royal Bank of Canada dropped their target price on shares of Hologic from $74.00 to $72.00 and set a “sector perform” rating for the company in a research report on Friday, November 10th. Finally, StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, January 18th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $86.89.

Check Out Our Latest Report on Hologic

Hologic Stock Up 0.8 %

NASDAQ HOLX opened at $74.06 on Tuesday. The stock has a market cap of $17.38 billion, a PE ratio of 35.10, a P/E/G ratio of 2.48 and a beta of 1.02. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The business has a 50 day moving average price of $72.20 and a two-hundred day moving average price of $71.88. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLXGet Free Report) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. Hologic’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.07 EPS. As a group, sell-side analysts predict that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares in the company, valued at approximately $7,793,700. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Essex D. Mitchell sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $71.85, for a total transaction of $538,875.00. Following the completion of the transaction, the insider now directly owns 12,827 shares in the company, valued at approximately $921,619.95. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The disclosure for this sale can be found here. Insiders sold a total of 32,440 shares of company stock worth $2,346,475 in the last 90 days. 1.75% of the stock is owned by company insiders.

Hologic Company Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

See Also

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.